InsidersTradesSigma
Follow the Grace Therapeutics, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €44.6m. The latest transaction was reported on 1 September 2026 (50 - Grant of options). Among the most active insiders: DelAversano, Robert John. The full history is accessible without an account.
Analysts rate Grace Therapeutics, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$6.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
7 of 7 declarations
Grace Therapeutics, Inc. is a company focused on developing innovative therapies. It is listed on the XNAS market.